synendos

Synendos Therapeutics: First-in-class endocannabinoid modulators to restore natural functioning of the brain in CNS disorders.

[synendos @synendos]

@Synendos is excited to announce the publication of the latest article written by @AndreaChicca and Jürg Gertsch, “CNS Drug Discovery in Academia: Where Basic Research Meets Innovation“ on @ChemBioChem.
#Biotech #Academia #drugdiscovery #ChemBioChem

[synendos @synendos]

We are excited to have received Clinical Trial Authorisation from the European Medicines Agency for our first-in-class Endocannabinoid System (ECS) modulator SYT-510
Learn more:https://t.co/oZvFhKwe5Q

#EndocannabionoidSystem #CentralNervousSystem #CTA #EMA #SERI #neuropsychiatry

[synendos @synendos]

Meet our CEO, Andrea Chicca, and CCO, Simon Russell, @Jefferies London Healthcare Conference next week, 14-16 November.
Please get in touch if you would like to meet with the @Synendos team at this important industry event.
#CNS #biotech #neuropsychiatry

[synendos @synendos]

@Synendos today announces that co-founder and SAB member Prof. Jürg Gertsch presented groundbreaking findings on an #endocannabinoid transporter at the 10th @GordonConf, informing and augmenting Synendos' pioneering ECS pipeline development.
Read more: https://t.co/Somn73pa6V

[synendos @synendos]

@Synendos is excited to support and participate in the 10th @GordonConf "Cannabinoids Function in the CNS" from 16-21st July 2023, with a talk from co-founder and scientific advisor member Prof. Jürg Gertsch.
#endocannabinoidsystem #CNS #Biotech
More info: https://t.co/ajpbeAbdmA

[synendos @synendos]

Synendos participates to the TOP 100 Swiss Start-ups Public Vote 2023!
Support our work in improving mental health care!
Voting is open, using your LinkedIn account, at https://t.co/ZJdb1Ve8Y6.

#TOP100SSU #BiotechInnovation #endocannabinoidsystem #CNS #entrepreneurship #teamwork

[synendos @synendos]

@synendos participates to the #BIO2023 International Convention, June 5-8. Meet our CEO/CSO Andrea Chicca and CCO Simon Russell to discuss the innovative approach to restoring brain physiology in #mentalhealth!
#CNS #biotech #innovation #endocannabinoidsystem #SERI #neuroscience

[synendos @synendos]

Our CEO & CSO Andrea Chicca will be speaking at BIO-Europe Spring 2023, March 21, 14:00 – 14:45 in Basel.
He will be the part of session “Navigating the Roadblocks of Biotech Entrepreneurship: Strategies for Startup Success”. Sharing his journey with Synendos Therapeutics AG.

[synendos @synendos]

Excited to participate at #BIOEuropeSpring 2023 in our hometown Basel, on March 20-22. Looking forward to meeting & connecting with you to discuss our novel approach to restoring physiological brain function.
#CNS #neuroscience #endocannabinoid #biotech #startups

[synendos @synendos]

It is a great honor to share that Synendos has been awarded with the prestigious @Innosuisse certificate, which indicates readiness for sustainable growths! #swissstartups #biotech #entrepeneurship #award #innovation #CNS #psychiatry #endocannabinoidsystem

[synendos @synendos]

Meet the @Synendos team during the #BIOEUROPE 2022 in Leipzig 24 – 26 October at the #SWISSPavilion #SwissBiotech, to discuss our first-in-class therapy to restore the healthy balance of brain physiology #biotech #neuroscience #CNS #endocannabinoid
https://t.co/wpHVLSZcU1

[Venturelab @venturelab_ch]

CELEBRATING all WINNERS of the #TOP100SSU Swiss Startup Award 2022: https://t.co/SPuTV1ZXYb
@SkribbleHQ
@sygnumofficial
@Synendos
@Synthara
@TerapetSA
@TerraQuantum_AG
@Threatray
@TinamuLabs
@TOLREMO
@TuneInsight
@TyxitAudio
@VisiumAI
@VoluminaMedical
@Yokoy_ai
@Zytlyn

[synendos @synendos]

Thank you @Innosuisse & @SGE for their continued support. We’re excited to be part of the Swiss delegation at #BIO2022 in San Diego on June 13-16, where we are looking forward to expanding our network of partners #biotech #CNS #neuroscience #endocannabinoid #SERIs @synendos

[synendos @synendos]

Read about the path that led @NCCR_TransCure and @Gertschlab to launch @synendos, an NCCR TransCure spin-off, representing a tangible result of the translational research, in their LAST newsletter #scientificnews #translationalmedicine #biotech #neuroscience #CNS #endocannabinoid

[LS2 section "Ion Channels & Membrane Transporters" @LS2_ICMT]

Looking for a pleasant reading for the weekend 📖? Then surf through our latest - and last! - @NCCR_TransCure newsletter! Learn about our "farewell fireworks" 🎆and further scientific news🔬from out network: https://t.co/DOxjfHc0XF

[synendos @synendos]

Synendos is present at the @SwissBioTech Days 2022! CEO @AndreaChicca will present @Synendos (Tue, 3. May 2:00-2:15 pm) as Emerging Biotech Company.

#sbd2022 #neuroscience #endocannabinoid #CNS #biotech

[synendos @synendos]

We are hiring!
We are looking for a Head of Translational Neuropharmacology.

👉To apply, check our website: https://t.co/LaAWq0i9SR

[Gebert Rüf Stiftung @grstiftung_ch]

With the support of #InnoBoosterGRS, @AndreaChicca and his team at @synendos are developing breakthrough safe and effective therapies for neuropsychiatric disorders such as anxiety, mood and stress-related disorders.
@unibern
https://t.co/ZXCHgCxXnt

[Venturelab @venturelab_ch]

Accounting for 33% of exports, life science is a major business in Switzerland. Innovation is strongly powered by biotech startups.
Meet the 15 companies that scored in the TOP 100 Swiss Startup Award 2021:
https://t.co/oJ2Lh8ZdGc
#TOP100SSU #SwissStartups #Biotech

[synendos @synendos]

We are hiring!
We are looking for a Head of Preclinical and Translational Neuropharmacology.

👉To apply, check our website: https://t.co/exC7gGC25s

[synendos @synendos]

Synendos is thrilled to announce the formation of the Scientific Advisory Board composed of prominent scientists and clinicians with significant CNS expertise.
#CNS #endocannabinoid #neurology #stressdisorders #neuropsychiatric

👉Full press release: https://t.co/SWQLHeli0J